옵션 체인은 다양한 행사가격과 만기일에 대한 Onconetix의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Onconetix에 대한 시장 심리를 평가합니다..

Onconetix (NASDAQ:ONCO) 주식, 옵션 체인

Onconetix

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Onconetix Inc

ONCO-INNOVATIONS LTD by ONCO-INNOVATIONS LTD.

ONCOPEPTIDES AB AK by ONCOPEPTIDES AB

OncoCyte Corp

ONCOSEC MEDICAL INC NEW by OncoSec Medical Incorporated

OncoSec Medical Inc

OncoSil Medical Ltd

ONCOVISTA INNVTVE THERPS by OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies Inc

ONCOLOGIX TECH INC by Oncologix Tech, Inc.

Oncologix Tech Inc

ONCOLOGY PHARMA INC by Oncology Pharma Inc.

Oncology Pharma Inc

Oncolytics Biotech Inc

Oncorus Inc rdinary Shares

ONCOTELIC THERAPEUTCS INC by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc

Press Releases

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

ENTO

ONCO

VRNA

Aditxt

Apollomics

Aptevo Therapeutics

Bone Biologics

Entero Therapeutics

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

SILO Pharma

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Theriva Biologics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Onconetix

Onconetix (ONCO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌